Pfizer and BioNTech vaccine 86% effective among older people after third dose

19 August 2021

Comirnaty, the COVID-19 vaccine from Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), is 86% effective in preventing infection among those aged 60 and older after a third dose, according to an Israeli study.

Initial results published by health maintenance organization Maccabi Health Services show that 37 people out of 149,144, or 0.02%, who received three doses have tested positive for COVID-19, compared to 1,064 of the 675,630 people, or nearly 0.2%, who only received a second jab in January or February of this year.

Maccabi, which insisted that it ensured that the two groups had similar demographics, found that the third doses were 86% effective after at least one week.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK